K S M Smalley

Summary

Publications

  1. pmc Rewired ERK-JNK signaling pathways in melanoma
    Pablo Lopez-Bergami
    Signal Transduction Program, The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Cancer Cell 11:447-60. 2007
  2. pmc CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
    K S M Smalley
    The Wistar Institute, Philadelphia, PA, USA
    Oncogene 28:85-94. 2009
  3. pmc Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Mol Cancer Ther 7:2876-83. 2008
  4. pmc Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 68:5743-52. 2008
  5. pmc Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
    K S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA
    Br J Cancer 96:445-9. 2007
  6. ncbi request reprint Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression
    Zhao Jun Liu
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 66:4182-90. 2006
  7. ncbi request reprint Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Mol Cancer Ther 5:1136-44. 2006
  8. doi request reprint The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
    Nikolas K Haass
    The Wistar Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 14:230-9. 2008
  9. ncbi request reprint Towards the targeted therapy of melanoma
    K S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Mini Rev Med Chem 6:387-93. 2006
  10. ncbi request reprint Life isn't flat: taking cancer biology to the next dimension
    Keiran S M Smalley
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    In Vitro Cell Dev Biol Anim 42:242-7. 2006

Collaborators

  • Noriaki Tanaka
  • MEENHARD I HERLYN
  • Katherine L Nathanson
  • Keith T Flaherty
  • Wafik S El-Deiry
  • Marcus Bosenberg
  • Y Wang
  • Johan Hansson
  • J Alan Diehl
  • DAVID ERIC ELDER
  • Ling Li
  • DAVID TUVESON
  • RAKESH F KUMAR
  • Maria S Soengas
  • Nikolas K Haass
  • Mercedes Lioni
  • Kazuhiro Noma
  • Alastair J King
  • James Tsai
  • Peng Xie
  • Katrin Sproesser
  • Min Xiao
  • Pablo Lopez-Bergami
  • Patricia Brafford
  • Zhao Jun Liu
  • Ben Powell
  • C Angelica Medina
  • John T Lee
  • Thiennga K Nguyen
  • Leslie Milk
  • Weiru Wang
  • Hanna Cho
  • Anil K Rustgi
  • Gaston Habets
  • Catherine Luu
  • Yoshihisa Suzuki
  • Calvin Settachatgul
  • Andres Klein-Szanto
  • Peter Hirth
  • Ivana Cheung
  • Julie Rice
  • Prabha N Ibrahim
  • Billy Lam
  • Hoa Nguyen
  • Hiroshi Nakagawa
  • Rooha Contractor
  • Ryan Bremer
  • Daniel Fong
  • Jun Kong
  • John Cantwell
  • Kam Y J Zhang
  • Ronen Marmorstein
  • Dean R Artis
  • Joseph Schlessinger
  • Adhirai Marimuthu
  • Sam Gillette
  • Douglas S Williams
  • Rafe Shellooe
  • Gideon Bollag
  • Andrew Snyder
  • Jiazhong Zhang
  • Eric Meggers
  • Shumeye Mamo
  • Brian L West
  • G Ekin Atilla-Gokcumen
  • Yoshio Naomoto
  • Yong Liang Zhu
  • Chao Zhang
  • Jennifer Liu
  • Sung Hou Kim
  • Alka Mahale
  • Alexey Eroshkin
  • Stuart Aaronson
  • James S Goydos
  • Anil Rustgi
  • Conway Huang
  • Dana Yip
  • ZE EV RONAI
  • Menashe Bar-Eli
  • Claudia Andl
  • Pearl S Huang
  • Klara Balint
  • Lusong Luo
  • Jae Lee
  • Erin Hugger
  • Michael M Morrissey
  • David Chau
  • Xueli Li
  • Cynthia M Rominger
  • Chelsea C Pinnix

Detail Information

Publications28

  1. pmc Rewired ERK-JNK signaling pathways in melanoma
    Pablo Lopez-Bergami
    Signal Transduction Program, The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Cancer Cell 11:447-60. 2007
    ..Our data reveal that, in human melanoma, the rewired ERK signaling pathway upregulates JNK and activates the c-Jun oncogene and its downstream targets, including RACK1 and cyclin D1...
  2. pmc CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
    K S M Smalley
    The Wistar Institute, Philadelphia, PA, USA
    Oncogene 28:85-94. 2009
    ..In summary, we have identified a group of melanomas with low-activity BRAF mutations that are reliant upon CRAF-mediated survival activity...
  3. pmc Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Mol Cancer Ther 7:2876-83. 2008
    ....
  4. pmc Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 68:5743-52. 2008
    ..This group of melanomas may be a subpopulation for which imatinib or other KIT inhibitors may constitute optimal therapy...
  5. pmc Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
    K S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA
    Br J Cancer 96:445-9. 2007
    ..Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies...
  6. ncbi request reprint Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression
    Zhao Jun Liu
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 66:4182-90. 2006
    ..Our data show regulation of MAPK/PI3K-Akt pathway activities and expression of N-cadherin by the Notch pathway and provide a mechanistic basis for Notch signaling in the promotion of primary melanoma progression...
  7. ncbi request reprint Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Mol Cancer Ther 5:1136-44. 2006
    ..It is further suggested that BRAF mutational status is not predictive of response to MEK inhibition under three-dimensional culture conditions...
  8. doi request reprint The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
    Nikolas K Haass
    The Wistar Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 14:230-9. 2008
    ..This study addresses the anti-melanoma activity of the MEK inhibitor AZD6244 (ARRY-142886)...
  9. ncbi request reprint Towards the targeted therapy of melanoma
    K S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Mini Rev Med Chem 6:387-93. 2006
    ..The recent years have seen great advances in understanding the biology of melanoma. In the current review we discuss the most promising molecular targets for melanoma and suggest possible strategies for overcoming resistance...
  10. ncbi request reprint Life isn't flat: taking cancer biology to the next dimension
    Keiran S M Smalley
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    In Vitro Cell Dev Biol Anim 42:242-7. 2006
    ..It is likely that the adoption of these and other 3D models will allow us to more closely re-create the behavior of the tumor in vivo which may lead to identifying better anticancer drug candidates at an earlier stage of development...
  11. pmc The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis
    Kazuhiro Noma
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Gastroenterology 134:1981-93. 2008
    ..Esophageal squamous cell carcinoma (ESCC) is known to be a highly angiogenic tumor. Here, we investigated the role of the stromal fibroblasts in the ESCC-induced angiogenic response using a novel 3-dimensional model...
  12. pmc Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells
    Mercedes Lioni
    The Wistar Institute, 3601 Spruce St, Philadelphia, PA 19104, USA
    Am J Pathol 170:709-21. 2007
    ..We also demonstrate a critical role for claudin-7 expression in the regulation of E-cadherin in these cells, suggesting this may be one mechanism for the loss of epithelial architecture and invasion observed in esophageal SCC...
  13. ncbi request reprint Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Ann N Y Acad Sci 1059:16-25. 2005
    ..In the current review, we discuss the role for these signaling pathways in melanoma and discuss the rationale for targeting signaling cascades using small molecule inhibitors...
  14. ncbi request reprint Targeting the stromal fibroblasts: a novel approach to melanoma therapy
    Keiran S M Smalley
    The Wistar Institute, Philadelphia, PA 19104, USA
    Expert Rev Anticancer Ther 5:1069-78. 2005
    ..More recent thinking posits that, although cancers are initiated through genetic mutation, progression is often the result of dynamic interactions between the tumor cells and their surrounding environment...
  15. pmc Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion
    Keiran S M Smalley
    Wistar Institute, 3601 Spruce St, Philadelphia, Pennsylvania 19104, USA
    Am J Pathol 166:1541-54. 2005
    ....
  16. ncbi request reprint Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions
    Keiran S M Smalley
    The Wistar Institute, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 123:xvi-xvii. 2004
  17. pmc Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity
    Peng Xie
    Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    ACS Chem Biol 3:305-16. 2008
    ....
  18. ncbi request reprint The great escape: another way for melanoma to leave physiological control?
    Keiran S M Smalley
    The Wistar Institute, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 121:xi-xii. 2003
  19. ncbi request reprint The role of altered cell-cell communication in melanoma progression
    Nikolas K Haass
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    J Mol Histol 35:309-18. 2004
    ....
  20. ncbi request reprint Is ERK activation a good biomarker for estradiol and tamoxifen effects?
    Keiran S M Smalley
    Wistar Institute, Philadelphia, Pennsylvania, USA
    Cancer Biol Ther 6:119-20. 2007
  21. ncbi request reprint An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 67:209-17. 2007
    ..Taken together, our data provide a new strategy for the pharmacologic activation of p53 in melanoma, which may be a viable approach for overcoming apoptotic resistance in melanoma and offer new hope for rational melanoma therapy...
  22. ncbi request reprint Adhesion, migration and communication in melanocytes and melanoma
    Nikolas K Haass
    The Wistar Institute, Philadelphia, PA 19104, USA
    Pigment Cell Res 18:150-9. 2005
    ....
  23. pmc Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway
    Mercedes Lioni
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Mol Cancer Ther 7:2866-75. 2008
    ..We therefore suggest that p38 MAPK pathway activation is an excellent potential therapeutic strategy in ESCC. It is further suggested that bortezomib could be added to existing ESCC therapeutic regimens...
  24. pmc Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    James Tsai
    Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Proc Natl Acad Sci U S A 105:3041-6. 2008
    ....
  25. ncbi request reprint Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
    Alastair J King
    Department of Oncology, MMPD CEDD, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
    Cancer Res 66:11100-5. 2006
    ....
  26. ncbi request reprint A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
    Keiran S M Smalley
    Section of Medicine, Institute of Cancer Research, London, United Kingdom
    Int J Cancer 104:527-32. 2003
    ..The aim of the current review is to assess the role of ERK in melanoma behaviour and to determine whether modulation of these kinases could offer new therapeutic opportunities...
  27. ncbi request reprint Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells
    Keiran S M Smalley
    Section of Medicine, Institute of Cancer Research, London, England
    Int J Cancer 105:165-75. 2003
    ....
  28. ncbi request reprint Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects
    Keiran S M Smalley
    Section of Medicine, Institute of Cancer Research, London, England
    Int J Cancer 98:514-22. 2002
    ....